BioMimetic Therapeutics, Inc. (NASDAQ: BMTI)
Franklin, TN  37067
http://www.biomimetics.com/
52-week low / high: $7.44 / $19.25
Shares Outstanding:  18.31 million
Market Capitalization:  $244.23 million

BioMimetic Therapeutics, Inc. is in the process of commercializing breakthrough therapies to aid in musculoskeletal injury and disease healing. The company has developed a unique drug-delivery system, which combines recombinant proteins and a tissue-scaffold to stimulate healing and tissue regeneration. BioMimetic’s first product, Growth-factor Enhanced Matrix (GEM 21S) received U.S. FDA approval in 2005 for the treatment of bone loss and gum recession as a result of periodontal disease.

In February, BioMimetic received orphan drug designation from the FDA for rhPDGF-BB for the treatment of osteonecrosis of the jaw. In June the company received approval to begin evaluation of GEM OS1 Bone Graft in foot and ankle fusions.

Future products under development include a synthetic bone regeneration system, GEM 21S (for which the company received marketing approval in Canada in September 2006) and GEM OS2 Injectable Bone Graft, for radius bone fractures (currently being evaluated in Sweden).

BioMimetic currently has manufacturing supply agreements with Novartis, Orthovita, Inc. and Kensey Nash for key bio-active and synthetic scaffolding component products.

While sales have declined year to year, most analysts see 2007 as a major turnaround year for BioMimetic, with sales expected to reach $7.5 million in 2007, up from $4.1 million in 2006 and growing to $12.3 million in 2008. Annual growth rate is seen around 30%. We believe the company has remarkably bright prospects.